ARCHIVES

Brigham & Women’s Suspends Controversial Morcellation Study As Apparent “Difference of Opinion” with FDA Comes to Light

This article is from The Cancer Letter archive.

Vol. 40 No. 45 | December 5, 2014

Download PDF Visit The Full Archive

Related Articles

Phase II Elotuzumab Study Demonstrates 33 Months PFS

July 26, 2013

NCAB Ponders Patient Accrual Problems, Members Irate Over System That Discourages Participation

February 19, 1988

In Brief: Sparano Named Vice Chair of ECOG-ACRIN

May 17, 2013

White House Okays Committee ‘Kill’ Lists; Workshops To Plan Projects In Carcinogenesis

July 22, 1977

Four More COP Awards Announced

January 9, 1981

NCI Reorganization Proposals Create opposition Among Some Advisors

June 17, 1988